Nature Communications (Jan 2023)
A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression
- Shohei Takase,
- Takashi Hiroyama,
- Fumiyuki Shirai,
- Yuki Maemoto,
- Akiko Nakata,
- Mayumi Arata,
- Seiji Matsuoka,
- Takeshi Sonoda,
- Hideaki Niwa,
- Shin Sato,
- Takashi Umehara,
- Mikako Shirouzu,
- Yosuke Nishigaya,
- Tatsunobu Sumiya,
- Noriaki Hashimoto,
- Ryosuke Namie,
- Masaya Usui,
- Tomokazu Ohishi,
- Shun-ichi Ohba,
- Manabu Kawada,
- Yoshihiro Hayashi,
- Hironori Harada,
- Tokio Yamaguchi,
- Yoichi Shinkai,
- Yukio Nakamura,
- Minoru Yoshida,
- Akihiro Ito
Affiliations
- Shohei Takase
- Laboratory of Cell Signaling, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences
- Takashi Hiroyama
- Cell Engineering Division, RIKEN BioResource Research Center
- Fumiyuki Shirai
- Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science
- Yuki Maemoto
- Laboratory of Cell Signaling, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences
- Akiko Nakata
- Drug Discovery Seed Compounds Exploratory Unit, RIKEN Center for Sustainable Resource Science
- Mayumi Arata
- Chemical Genomics Research Group, RIKEN Center for Sustainable Resource Science
- Seiji Matsuoka
- Drug Discovery Seed Compounds Exploratory Unit, RIKEN Center for Sustainable Resource Science
- Takeshi Sonoda
- Drug Discovery Seed Compounds Exploratory Unit, RIKEN Center for Sustainable Resource Science
- Hideaki Niwa
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research
- Shin Sato
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research
- Takashi Umehara
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research
- Mikako Shirouzu
- Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research
- Yosuke Nishigaya
- Watarase Research Center, Discovery Research Headquarters, Kyorin Pharmaceutical Co. Ltd.
- Tatsunobu Sumiya
- Watarase Research Center, Discovery Research Headquarters, Kyorin Pharmaceutical Co. Ltd.
- Noriaki Hashimoto
- Watarase Research Center, Discovery Research Headquarters, Kyorin Pharmaceutical Co. Ltd.
- Ryosuke Namie
- Watarase Research Center, Discovery Research Headquarters, Kyorin Pharmaceutical Co. Ltd.
- Masaya Usui
- Support Unit for Bio-Material Analysis, Research Resources Division, RIKEN Center for Brain Science
- Tomokazu Ohishi
- Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation
- Shun-ichi Ohba
- Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation
- Manabu Kawada
- Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation
- Yoshihiro Hayashi
- Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences
- Hironori Harada
- Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences
- Tokio Yamaguchi
- RIKEN Program for Drug Discovery and Medical Technology Platforms
- Yoichi Shinkai
- Cellular Memory Laboratory, Cluster for Pioneering Research
- Yukio Nakamura
- Cell Engineering Division, RIKEN BioResource Research Center
- Minoru Yoshida
- Drug Discovery Seed Compounds Exploratory Unit, RIKEN Center for Sustainable Resource Science
- Akihiro Ito
- Laboratory of Cell Signaling, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences
- DOI
- https://doi.org/10.1038/s41467-022-35404-0
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 18
Abstract
This study describes RK-701, an inhibitor of histone methyltransferases G9a/GLP, as a promising therapeutic candidate for sickle cell disease and a universal role of BGLT3 lncRNA in fetal hemoglobin reactivation by chemical inducers including RK-701.
